Review

The role of circular RNAs in brain and stroke

Yu-Ye Wang¹, Yan-Zhe Wang^{1,2}, He-Yu Zhang^{3,*}, Zhi-Yi He^{1,*}

¹Department of Neurology, Key Laboratory for Neurological Big Data of Liaoning Province, The First Affiliated Hospital of China Medical University, 110001 Shenyang, Liaoning, China, ²Department of Pharmacology, School of Pharmacy, China Medical University, 110122 Shenyang, Liaoning, China, ³Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, No.58 Zhongshan Road 2, 510080 Guangzhou, Guangdong, China

TABLE OF CONTENTS

- 1. Abstract
- 2. Introduction
- 3. circRNAs biogenesis and its regulation
- 4. Function of circRNAs
 - 4.1 Function as miRNA sponges
 - 4.2 Gene transcription regulation
 - 4.3 Encode protein or peptide directly
 - 4.4 Function as biomarkers
- 5. circRNAs in the brain
- 6. circRNAs and stroke
 - 6.1 circRNAs and IS
 - 6.2 circRNAs and ICH
- 7. Perspective
- 8. Author contributions.
- 9. Ethics approval and consent to participate
- 10. Acknowledgment
- 11. Funding
- 12. Conflict of interest
- 13. References

1. Abstract

Circular RNAs are single-stranded RNAs which are closed by covalent bonds during splicing. Different from other RNAs, circular RNAs are well known due to their circular structure. In recent years, many researches were conducted to investigate the role of circular RNAs in multiple diseases. To better understand the structure of circular RNAs, we reviewed the biogenesis and related regulation at first. Mechanisms by which circular RNAs exert effects were summarized then. Due to the conserved and brain-specific characteristic, circular RNAs in brain were depicted next. At last, considering the high mortality rate and disability rate caused by stroke globally, we reviewed related articles and summarized the results of original articles. Circular RNAs are suggested to be involved in the pathogenesis of stroke as well as some other neurological diseases which provides new insights and potential targets in clinical application.

2. Introduction

Circular RNAs (circRNAs) are single-stranded RNAs which are closed by covalent bonds during splicing. circRNAs was discovered decades ago. However, because of the lack of free 3' and 5' ends which are different from linear RNA, circRNAs cannot be detected by molecular technology dependent on poly-adenylated (poly A) tail. Therefore, only a small amount of circRNAs are found. At first, circRNAs are regarded as the by-products of aberrant splicing, with almost no biological function. But powered by advanced high-throughput RNA sequencing in recent years, circRNAs are found to express in eukaryotic cells universally. At the same time, more and more studies start focusing on the function of circRNAs, which reveals

Submitted: 28 October 2020 Accepted: 16 December 2020 Published: 30 April 2021 This is an open access article under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/). © 2021 The Author(s). Published by BRI. that circRNAs are involved in gene regulation [1, 2].

According to the related current researches, the characteristic of circRNAs are as follows: ①Huge amount and widely expressed: High-throughput sequencing (HTS) reveals the universal expression of tens of thousands of circRNAs in Metazoa, from fruit flies and worms to ro-dents and humans; ②Highly stable: the circular structure prevents the circRNAs from the cleavage of branching enzymes and exonucleases [3]; ③Highly conserved: many circRNAs have highly conserved sequences that can be detected not only in humans but also in rodents [3]; ④Tissue-specific: researches show that the circRNAs are represented at a high level in neural tissues [1, 4, 5].

Stroke is a major cause of death and disability worldwide, particularly in developing countries [6]. Ischemic stroke (IS) and intracerebral hemorrhage (ICH) are two subtypes of stroke. IS occurs when blood supply to a certain area of the brain is obstructed or reduced, usually caused by a thrombus. ICH causes brain injury characterized by neuronal death and blood brain barrier breakdown mainly by two mechanisms. Primary brain injury was caused by the repression and destruction of hematoma to brain tissue while inflammation response and release of clots components cause secondary brain injury [7]. Currently, treatments for stroke are limited. Further understanding the pathophysiological mechanism of the development of stroke might provide a new and more effective way to diagnose stroke and improve outcomes. Most non-coding RNA based strategies and related researches mainly concentrate on long non-coding RNAs and microR-NAs (miRNAs) [8, 9]. Recently, several researches suggested the roles of circRNAs in stroke.

In conclusion, circRNAs participate in neural regulation and stroke pathogenesis. This review summarizes the result of recent researches and reviews the biogenesis and function of circRNAs. Furthermore, we discussed the role of the circRNAs in the brain in order to highlight the significance of circRNAs in neural system. At last, we focused on the effect of circRNAs in stroke which would provide new target for diagnosis and treatment.

3. circRNAs biogenesis and its regulation

Based on the constituent components, circRNAs could be categorized into three types: circular exonic RNAs (ecircRNAs), circular intronic RNAs (ciRNAs) and exonintron circular RNAs (EIciRNAs).

EcircRNAs, which consist of only exon sequences, are mainly expressed in cytoplasm. They are highly stable whose half-life are more than 48 hours. Bioinformatics analysis suggested common characteristic of cyclized exons, in which adjacent flanking introns contained more complementary ALU repeats than non-circularized exons [3]. There are two main biogenesis mechanisms: ①Direct back-splicing: Pairing between complementary sequences from the flanking introns promotes the formation of an exon loop in which the downstream 5' splice donor site is joined to an upstream 3' splice acceptor site. (2)Exon skipping [10]: During the exon skipping process, a lariat structure including exons is formed, and then undergoes the internal splicing where introns are excised and ecircRNAs are generated. Most circRNAs under research are this type of circRNAs.

ciRNAs, composed of intron sequences, mainly locate in the nucleus. The processing depends on a conserved consensus motif which contains a 7 nt GU-rich element near the 5' splice site and an 11 nt C-rich element close to the branch-point site [11]. There are three main biogenesis mechanisms: ①group II introns are excised as ciRNAs through the form of a 2',5'-phosphodiester bond; ②group I introns undergo self-splicing starting with nucleophilic attack of exogenous guanosine (exoG) onto the 5' splice site, followed by 3'-terminal guanosine (ω G) nucleophilic attacking onto a phosphodiester bond close to the 5'-end of the intron. Exons are ligated, and group I introns are circularized; ③ full length ciRNAs are generated by the hydrolysis of the exon at the 3 'splice site, followed by the ω G nucleophilic attacking onto the 5' splice site [10].

EIciRNAs, composed of exon and intron sequences, mainly present in the nucleus [12]. Derived from messenger RNA precursors (pre-mRNA), EIciRNAs is formed by back-splicing [1, 13], whose content is much lower than homologous mRNA.

Derived from mRNA precursor, circRNAs are transcribed by RNA polymerase II (Pol II), which is related with Pol II transcription elongation rate [14]. circRNAs biogenesis are mainly regulated by the cis-regulatory elements and trans-acting factors which control splicing [1]. It is noteworthy that both circRNAs and classical linear RNA are generated by pre-mRNA through post-transcriptional regulatory mechanisms, which suggests that there is a competitive relationship between the two during the generation [15]. In addition, RNA binding protein regulates the production of circRNAs. For example, muscleblind protein (MBL) can promote the cyclizing of the exon of MBL gene [15]; Quaking protein (QKI) can up-regulate the expression level of a variety of circRNAs during the process of epithelial-mesenchymal transition (EMT) [16].

4. Function of circRNAs

4.1 Function as miRNA sponges

Some ecircRNAs are expressed stably and are rich in contents. They have miRNAs binding sites, which can compete with mRNA and thus regulate gene expression [1, 3]. The most typical example is ciRS-7 [17], which is derived from cerebellar degeneration related 1 (CDR1). antisense transcript and is mainly found in the brains of humans and mice [18]. It contains over 60 conserved miR-7 binding site [19]. ciRS-7 was highly expressed in the cytoplasm and can bind up to 20,000 miR-7 molecules per cell [19], which might affect the binding of miR-7 to its target mRNA. Reduced expression of ciRS-7 resulted in decreased expression of mRNAs which contain miR-7 binding sites, which confirmed that mRNAs compete with ciRS-7 for miR-7 binding sites [18, 19]. In addition, the function of ciRS-7 was conserved, and ciRS-7 expression in zebrafish affected the development of midbrain, whose effect was consistent with miR-7 knockdown [1, 19]. However, a recent article published in Science pointed out that after ciRS-7 knockout in mice, expression level of miR-7 in the cerebral cortex, hippocampus, cerebellum, and olfactory bulb significantly reduced, while the downstream target gene Fos was upregulated. Thus, it can be seen that the mechanism related to miRNA sponge function remains to be explored [20]. In addition, sex-determining region Y of testicular-specific circRNA (circSRY) contains 16 miR-138 binding sites in the mouse brain [18]. circZNF91, originating from zinc finger protein gene contains 24 miR-23 binding sites and 39 miR-296 binding sites [21]. Generally speaking, circRNA derived from genes containing repeat coding regions contains a series of conserved miRNA binding sites [22].

4.2 Gene transcription regulation

Different from ecircRNAs, ciRNAs and EIciR-NAs mainly exist in the nucleus. However, its mechanism of transportation and retention in the nucleus is unclear. In human cells, ciRNAs localize near the host gene and combine with RNA Pol II during transcription, which increased the level of transcription through a mechanism of cis-regulation [23]. Studies have found that knockdown of ciRNAs would result in decreased expression of parental mRNA. Similarly, EIciRNAs can also interact with RNA Pol II. Knocking down EIciRNAs can also reduce the mRNA expression level of their parental gene. EIciR-NAs associate with U1 small nuclear ribonucleoprotein (snRNP) through characteristic RNA-RNA interaction between EIciRNA and U1 small nuclear RNA (snRNA). Then the EIciRNA-U1 snRNP complexes may further communicate with the Pol II transcription complex at the promoters of parental genes, thereby increasing gene expression [12, 13]. circNOL10 was reported to promote transcription factor (TF) sex comb on midleg-like 1 (SCML1) expression by inhibiting ubiquitination [24].

4.3 Encode protein or peptide directly

circRNAs were originally considered as a special type of non-coding RNAs, but several researches have pointed out that circRNAs can be translated into proteins. In 1995, it was reported that eukaryotic ribosomes can start translation on circRNAs when the RNAs contain internal ribosome entry site (IRES) elements. Recently, a circRNA derived from the muscleblind locus was suggested to encode a protein in fly head when extracted by mass spec-

trometry [25]. CircZNF609 contained a 753-nt open reading frame (ORF), which was similar to linear transcripts, starting from AUG of the host gene and ending with a stop codon [26]. CircZNF609 interacted with polysomes, and then translated into a protein in a splicing-dependent and cap-independent manner [27]. Besides, circFBXW7 was highly expressed in the normal human brain. The spanning junction ORF in circ-FBXW7 driven by internal ribosome entry site encoded a novel protein, FBXW7-185aa, which is a functional protein. Increased expression of FBXW7-185aa in cancer cells was found to inhibit proliferation and cell cycle acceleration, while downregulation of FBXW7-185aa promoted malignant phenotypes both in vivo and in vitro. FBXW7185aa could also decrease the half-life of c-Myc by inhibiting USP28-induced c-Myc stabilization. Findings above suggested that circ-FBXW7 and FBXW7-185aa have potential prognostic significance in brain tumor [28]. Another novel tumor suppressor protein, SHPRH-146aa, consistent with the full-length protein and behaving as a protective molecule to decrease degradation, was derived from circ-SHPRH driven by IRES elements [29]. Besides, circ β -catenin could produce a novel 370-amino acids β -catenin isoform which shared the same start codon with the linear mRNA transcript but ended at a new stop codon when cyclizing. Silencing of $circ\beta$ -catenin significantly suppressed malignant phenotypes both in vivo and in vitro, while knockdown reduced the protein expression level of β -catenin without influencing its mRNA level which further validates the possibility of circRNAs translation [30]. In addition, poly-adenosine or poly-thymidine in 3' UTR could inhibit circRNAs translation [31] and m6A motif was found to initiate translation in endogenous circRNAs with translation potential in cellular responses to environmental stress [32]. The correlated mechanism is shown in Fig. 1.

4.4 Function as biomarkers

Considering circRNAs are stable and expressions are cell-specific, selectively abundant and varying in different diseases, circRNAs are expected to have the potential to be a biomarker [33]. circRNAs were identified in several kinds of fluids, including exosomes [34], saliva [35], and blood [36]. Actually, circRNAs were suggested to behave as biomarkers in a variety of diseases, including cancer [34], systemic lupus erythematosus [37], rheumatoid arthritis [38], diabetes [39] and tuberculosis [40]. In addition, in the condition of nervous system diseases, such as Alzheimer's disease (AD) [41], stroke [42] and amyotrophic lateral sclerosis (ALS) [43], blood-brain barriers are easy to be damaged, allowing free or exosomeencapsulated circRNAs [44] to release from the brain and be measured peripherally. Therefore, in neurological diseases, brain-specific circRNAs might be released into the circulatory system, so that the level of circRNAs in the blood can be used to monitor disease progression or achieve therapeutic purposes.



Fig. 1. Three possible mechanisms that circRNAs exert functions. (A). Function as miRNA sponges. circRNAs could interact with miRNAs and further relieve the suppression of target genes by miRNAs. (B). Gene transcription regulation. circRNAs have binding sites of RNA binding protein. They could interact with U1 snRNP, RNA Pol II or transcription factors and then regulate gene transcription. (C). Encode protein or peptide directly. circRNAs might transcript into peptides or proteins and proteins play a role directly.

5. circRNAs in the brain

circRNAs are conserved in sequence in the mammalian brain, either in humans and mice [45], and sometimes can be detected even in the brain of drosophila [5]. To comprehensively identify the tissue-specific expression of mammalian circRNAs, You *et al.* performed a thorough sequencing analysis of total RNA samples (excluding rRNA) from several mouse tissues (i.e., brain, liver, lung, heart, and testis). In all tissues they examined, circRNAs content was clearly the highest in brain. Either in the percentage of circular junction reads from all the reads mapped on the genome, or the percentage of genes that generated circRNAs from all the expressed genes, brain ranked the highest with 0.75–0.87% and 20–21%, respectively. Both higher exclusively expression of circRNAs host genes in brain [45, 46] and a higher contribution of circRNAs in brain when a host gene is universally expressed in many tissues lead to the higher enrichment of circRNAs in brain [46]. This illustrates that circRNAs are highly conserved and brain-specific, which provide the basis for performing research in rats or mice and reveal the validation and significance of conducting circRNAs-related study in brain.

In human fetal brain tissue, there are on average 8914 tissue-specific circRNAs per sample which is the most abundant in fetal tissues and suggests an important role in brain development [45]. During neuronal differential, stable-state level of circRNAs significantly upregulated as indicated by their total number and expression while the level of linear mRNAs kept almost unchanged [14]. A research divided rhesus macaque into two age groups-adult (10-year) and aged (20-year) Totally, 17,050 well-expressed, stable circRNAs were found. Approximately 3% (475/17050) age-different circRNAs, including 272 20y-specific and 203 10y-specific, were found during brain aging [47] which indicates an aged accumulation of circRNAs in aging brain [47, 48]. Besides, eight anatomical brain compartments were deeply sequenced. Cerebellar circRNAs are different from that of other areas which revealed a spatial-specific characteristic [47]. Sex-biased expression of circRNAs was also found in rhesus macaque brain which is similar to protein differential expression in human brain [47].

In addition, studies have suggested that circR-NAs are enriched in synaptosomes [5, 46]. High-resolution in situ hybridization was used for validation while circRNAs were visualized in cultured hippocampal neurons. CircHomer1 a is a circRNA generated from the synaptic scaffolding molecule Homer1 transcript. The result of in situ hybridization revealed abundant expression of circHomer1_a in both neuropil and somata layers of CA1 hippocampal region. Besides, many circRNAs upregulate their expression levels abruptly during synaptogenesis. During development of hippocampus, upregulated circRNAs were generated from the gene loci that also coded for proteins enriched with synapse-related functions. Results of highthroughput sequencing, quantitative reverse transcription polymerase chain reaction (qRT-PCR) and in situ hybridization are consistent with each other. All indicated that circR-NAs expression is developmentally regulated [46]. However, the regulation of circRNAs was independent of their host genes which indicate the specific role of circular structure. In summary, a change in the expression pattern for many circRNAs related with the beginning of synaptogenesis was observed which suggests a role of circRNAs in development of hippocampus.

6. circRNAs and stroke

6.1 circRNAs and IS

Many studies have reported circRNAs microarrays or sequencing results which are related with IS. After validation by qRT-PCR, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were performed. Several researches were conducted in patients and healthy controls while the others used rodent models or cells. In human sample, the ratio of serum hsacircRNA-284 and miR-221 was found to notably increase in the patients of IS within 5 days (P = 0.0002), which had a biomarker potential of carotid plaque rupture and stroke

[49]. Ostolaza et al. found that a set of 60 circRNAs were increased in atherotrombotic compared with cardioembolic strokes. Differential expression of hsa-circRNA-102488 which is originated from UBA52 gene, was further validated. This suggests that circRNA might be a new source of biomarker for IS etiology [50]. Moreover, circFUNDC1, circPDS5B and circCDC14A were increased in IS patients versus healthy controls and were reported to serve as diagnostic and prognostic biomarkers [51]. In addition, 373 circRNAs were increased, while 148 were decreased when compared the peripheral blood mononuclear cells (PBMCs) from IS patients versus healthy controls. Thirteen candidate circRNAs were verified by qRT-PCR. Bioinformatics analysis showed that aberrantly expressed circRNAs were associated with inflammation and immunity which were involved in IS pathogenesis and had the potential to be diagnostic biomarker [52]. While using rodent models, 128, 198, and 789 circRNAs were found to be significantly changed at 5 min, 3 h, and 24 h after IS in mice blood sample. After validation by IS patient blood sample, hsa-circ-0090002 and hsa-circ-0039457 were reported to be differentially downregulated [53]. Besides, after 45minute-transient middle cerebral artery occlusion (MCAO), circRNA microarrays revealed that 1027 circRNAs were significantly changed in 48 hours after reperfusion in the ischemic brain versus the sham group in which 914 circR-NAs were notably increased, while the other 113 were notably decreased. The expression level of mmu-circRNA-40001, mmu-circRNA-013120, and mmu-circRNA-40806 was further validated by qRT-PCR. After GO and KEGG analyses, the Rap1 and Hippo signaling pathway which are involved in cell survival and death regulation was found to be the most enriched [54]. In another microarray analysis, 283 circRNAs were changed (>2-fold) at least at one of the reperfusion time points, whereas 16 were changed at all 3-time points (6 h, 12 h and 24 h) of reperfusion after transient MCAO studied versus sham. Then bioinformatics analysis showed that binding to proteins, ions and nucleic acids, cell communication, metabolic process, and biological regulation are leading biological and molecular functions regulated by circRNAs change after transient MCAO [55]. Duan et al. suggested that totally 14,694 circRNAs from 6 brain tissues were detected differentially expressed by HTS of which 87 showed a significant fold change >2 (P < 0.05). rno-circRNA-17737, rno-circRNA-8828 and rno-circRNA-14479 were significantly upregulated, while rno-circRNA-1059, rno-circRNA-9967 and rno-circRNA-6952 were significant downregulated when validated [56]. Zhang et al. reported that 16 and 28 circRNAs showed significant increase and decrease respectively in rat ischemia-reperfusion model by HTS. In in vitro experiments, levels of the hsa-circ-camk4 were elevated in SH-SY5Y cells exposed to oxygen-glucose deprivation/reoxygenation (OGD/R) treatment. Overexpression of hsa-circcamk4 in SH-SY5Y cells significantly in-

creased cell death rate after OGD/R. Bioinformatics analysis showed that circcamk4 was involved in the apoptosis signaling pathways, glutamatergic synapse pathway and MAPK signaling pathway, all of which are known to be included in brain injury after ischemia-reperfusion (I/R). This suggested that hsa-circ-camk4 may have been involved in in progression of cerebral I/R injury [57]. In parallel, 3 circRNAs were significantly increased, and 12 were decreased in HT22 cells with OGD/R compared with normal controls. Furthermore, upregulation of mmu-circRNA-015947 was validated by qRT-PCR. Bioinformatics analysis revealed that mmu-circRNA-015947 could interact with mmu-miR-188-3p, mmu-miR-329-5p, mmu-miR-3057-3p, mmu-miR-5098 and mmu-miR-683 and thus increase target gene expression. KEGG pathway analysis predicted that mmu-circRNA-015947 might be involved in apoptosis, metabolism and immune-related pathways, which are known to play a role in cerebral I/R injury [58]. The detailed information summary is shown in Table 1 [49-58]. Besides, circHECTD1 expression was upregulated in IS recurrence patients versus non-recurrence patients (160: 160). Further, ROC curve analysis indicated that circHECTD1 expression predicted higher risk of IS recurrence. CircHECTD1 also correlated with higher disease risk, disease severity and inflammation [59]. Similar results were found in peripheral blood mononuclear cell circDLGAP4. CircDLGAP4 is decreased and negatively related with severity, inflammatory cytokine expression such as TNF- α , IL-6, IL-8 as well as IL-22 and miR-143 expression in IS patients [60]. Moreover, in vitro, silencing of circHIPK2 stimulated neural stem cells (NSCs) specifically differentiated into neurons but made no difference to the differentiation to astrocytes. In vivo, microinjection of si-circHIPK2-NSCs could migrate to the ischemic area after stroke induction. Si-circHIPK2-NSCs increased neuronal plasticity in the ischemic brain, led to long-lasting neuroprotection, and significantly reduced functional dysfunction which exhibits a promising therapeutic strategy to neuroprotection [61]. The findings suggest that circRNAs might be a biomarker for IS diagnosis and involved in IS pathogenesis but the concise mechanism needs further investigation.

When it comes to the mechanism research, some studies indicate that circRNAs are involved in the process of IS by interacting with miRNAs and subsequent downstream target genes. CircDLGAP4 was found to be downregulated in IS patients and tMCAO mice and functioned as miR-143 sponge to repress miR-143 activity, which inhibited the expression of homologous to the E6-AP C-terminal (HECT) domain E3 ubiquitin protein ligase 1 (HECTD1). Overexpression of circDLGAP4 enhanced tight junction protein expression and decreased mesenchymal cell marker expression which inhibited endothelial-mesenchymal transition (EMT). and would lead to blood brain barrier (BBB). protection [62]. In parallel, circHECTD1 was upregulated

in tMCAO mice and functioned as an endogenous miR-142 sponge to repress miR-142 activity, resulting in the inhibition of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) inducible poly (ADP-ribose) polymerase (TIPARP) expression. The knockdown of circHECTD1 reduced infarct volumes and attenuated neurological deficits in transient MCAO mice through regulation of astrocyte activation via inhibition of autophagy [63]. Another associated study illustrated that circTLK1 functioned as an endogenous miR-335-3p sponge to repress miR-335-3p activity, which resulted in the increasing expression of TIPARP and a subsequent exacerbation of neuronal injury. The knockdown of circTLK1 significantly decreased infarction area, ameliorated neuronal injury, and improved neurological dysfunction [64]. Results are consistent with and complement each other, which provide new potential therapeutic targets for IS patients.

6.2 circRNAs and ICH

In ICH model, SD rats were injected with autologous artery blood. 111,1145,1751 circRNAs were upregulated while 47,732,1329 were downregulated in the cerebral cortex of ICH rats at 6 h, 12 h and 24 h after ICH induction compared with sham group (fold change \geq 1.5, *P*-value \leq 0.05). 93 were up-regulated and 20 were down-regulated at all three time points. The expression level of 6 circRNAs were further validated using qRT-PCR while 2 up-regulated circRNAs (rno_circRNA_011054 and rno_circRNA_005098) and 1 down-regulated circRNA (rno_circRNA_012556) were statistically altered. After GO and KEGG analyses, parent genes showed transition from protein complex assembly, cell-cell adhesion and cyclic adenosine monophosphate (cAMP) signaling pathway at 6 h to intracellular signal transduction, protein phosphorylation and glutamatergic synapse at 12 h and 24 h. Enrichment analyses of targeted mRNAs indicated transcriptional regulations and pathways including Ras-associated protein 1 (Rap1), mitogen-activated protein kinase (MAPK), phosphatidylinositol 3 kinase/protein kinase B (PI3K-Akt), tumor necrosis factor (TNF) and Wingless/Integrated (Wnt) signaling pathways in cancer [65]. Findings above suggest an important role of circRNAs in ICH and provide potential mechanism direction for further basic research and a promising target for ICH treatment.

circRNAs also participated in the pathogenesis of other neurological diseases, such as AD, Parkinson's disease (PD), motor neuron disease (MND) and demyelination diseases. In AD, many researches also focused on expression profiles [66–72]. Consistent with result above, majority of AD-associated circRNAs are independent from changes in cognate linear mRNA expression [66]. circR-NAs are found to play roles in AD [20, 73–77], either by interacting with proteins [73] or miRNAs [74, 75]. In PD, circDLGAP4 exerted neuroprotective effects via miR-134-5p/CREB pathway [78] while circzip-2 possible sponged

Study	Species-	Microarray or se- Differentially expressed circR- Validation sample	Differentially expressed GO enrichment and KEGG pathw	vay Interaction network of	Significance
no.	Model	quence sample NAs (Fold change, <i>P</i> -value).	circRNAs (Fold change, analysis	circRNA-miRNA-target	
			<i>P</i> -value).	genes	
1 [49]	Homo	24 asymptomatic: circR-284: miR-221, elevated 47 asymptomatic,	41 circR-284: miR-221, ele	-	serum circR-284: miR-
	sapiens-	17 urgent symp- in the urgent group ($P = urgent^{a}$ patients,	24 vated in the urgent group		221 might act as a diag-
	Human	tomatic IS 0.0002). other symptoma	tic ^o ($P < 0.001$).		nostic biomarker of carotid
		patients serum patients serum			plaque rupture and stroke
2 [50]	Homo	30 stroke patients 60 circRNAs upregulated and 25 atherotrombo	tic: Hsa-circRNA-102488 was RNA-, ion- and enzyme-bind	ing Hsa-circRNA-102488-	a new source of biomark-
	sapiens-	with different 159 circRNAs downregulated 25 cardioembolic	IS significantly downregu- molecules, a protein and nucleic a	cid following miRNAs: hsa-	ers of stroke etiology
	Human	stroke etiologies (FC \geq 1.5, <i>P</i> -value \leq 0.05). patients samples	lated in atherotrombotic binding transcription factor activ	ity miR-1182, hsa-miR-1299,	
		In atherotrombotic: cardioem-	stroke patients compared and to be involved in cellular nitrog	gen hsa-miR-431, hsa-miR-	
		bolic stroke patients venous	with cardioembolic sam- compound metabolic, biosynthe	tic, 516b, hsa-miR-668 and	
		blood sample; 87 circRNAs up-	ples when normalizing to cellular protein modification and ge	ene hsa-miR-766	
		regulated and 139 circRNAs	GAPDH mRNA (<i>P</i> -value expression processes; fatty acid bios	yn-	
		downregulated in atherotrom-	< 0.01), as well as to the thesis and metabolism, extracelly	ilar	
		botic: undetermined strokes $(PC) > 1 \in \mathbb{R}$	corresponding UBA52 matrix-receptor interaction, lys	ine	
		(FC \geq 1.5, <i>P</i> -value \leq 0.05);	mRNA (P -value < 0.001) degradation or arrhythmogenic ri	gnt	
		o clickivas were found to	(P < 0.001) ventricular cardioniyopauly		
		NA a wore deveryouted in			
		ardicembolic: undetermined			
		cardioembolic. undetermined			
3 [51]	Homo	3 IS patients: 3.10 were up-regulated and 68 Validation: 36 IS	na circEUNDC1 circPDS5B	_	(1) 3 circPNAs levels were
5[51]	sanions-	matched healthy were down-regulated circP- tients: 36 matched	nositively correlated with		
	Human	controls NAs (fold changes >4 and controls: Benlicat	ion: unregulated in IS nationts		infarct volume suggesting
	Tuniun	$P_{\text{values}} < 0.05$ 200 IS nations:	100 compared with healthy		as notential biomarkers
		matched controls	controls		for AIS diagnosis: (2)
			controls		change rate in circRNAs
					within the first 7 days of
					treatment could serve as
					a potential biomarker for
					predicting stroke outcome:
					(3) Elevations of cir-
					cPDS5B and circCDC14A
					in plasma might be de-
					rived from lymphocytes
					and granulocytes

Table 1. Detailed information summary of circRNAs expression profiles in IS.

				Table 1. Colluliueu	•		
Study no.	Species- Model	Microarray or se- Differentially expressed circR quence sample NAs (Fold change, <i>P</i> -value)	- Validation sample	Differentially exp circRNAs (Fold ch <i>P</i> -value)	ressed GO enrichment and KEGG phange, analysis	pathway Interaction network circRNA-miRNA-target genes	of Significance
4 [52]	Homo sapiens- Human	5 IS patients: 5 373 circRNAs were upregu healthy controls lated and 148 were downregu peripheral blood lated mononuclear cells	- 5 IS patients: - healthy control peripheral bloo mononuclear cells	5 four were upregulate s four were downregul d	ed and The pathways involved ated the metabolic pathways, the gen activated protein kinase (I signaling pathway, some inflar pathways (e.g., the nuclear H B (NF κB). signaling pathwa tumor necrosis factor (TNF). s pathway, and the chemokine s pathway), immune pathways (H Toll-like receptor signaling pathway), immune pathways as with cell proliferation, differe and apoptosis (e.g., the phospin nositol 3 kinase/protein kin signaling pathway, the Ras protein 1 signaling pathway, th signaling pathway, and the Janu signal transducer and activator scription signaling pathway); P of three domains: biological cellular component and m function	include 8 circRNAs-miRNAs e mito- MAPK). mmatory factor κ way, the signaling signaling e.g., the athway), ssociated intiation, hatidyli- nase B related he FoxO is kinase of tran- rocesses process, holecular	circRNAs in PBMCs ^c may be diagnostic biomarkers or potential therapeutic tar- gets

Table 1. Continued.

					Table 1. Continued	1.			44
Study no.	Species- Model	Microarray or se- quence sample	Differentially expressed circR- NAs (Fold change, <i>P</i> -value)	- Validation samp	e Differentially exp circRNAs (Fold c <i>P-</i> value)	ressed GO enrichment and KE hange, analysis	GG pathway Interaction circRNA-mil genes	network of Significance RNA-target	
5 [53]	Mus musculus- Mice	5 min, 3 h and 24 h MCAO ^{<i>d</i>} sham	1051, 782, and 2721 circRNA probes exhibited differential expression at 5 min, 3 h, and 24 h of MCAO	A Verification I MCAO iscl I brain tissue; V tion by IS pa and matched co blood sample	by hsa_circ_0090002 nemia (PHKA2) alida- hsa_circ_0039457 (tients were downreg ntrols (<i>P</i> = 0.001 and respectively).	circRNAs parental gene and MCAO, the major pathy BBS2) platelet-derived growth fa julated insulin, focal adhesion, an 0.01 signaling pathways. 3 h major pathways include gic synapse, calcium sig GnRH signaling. 24 h identified pathways includ gic synapse, calcium sig vascular smooth muscle CircRNAs-miRNAs-Targe 5 min MCAO, the majo functions were antioxida receptor, signal transduce porter activities; 3 h MCA functions were involved i tion of catalytic activity, involved in antioxidant a prominently increased; 2 most gene functions were with binding and cataly The stroke-related biologi included the immune proce process, and biological ac significant pathways after were associated with the 1 ing pathway, cytokine-cyto interaction, metabolism o by cytochrome P450, bi unsaturated fatty acids, a and mucin type O-glycan At 3 h, extracellular m -receptor interaction, m xenobiotics by cytochrom glycosphingolipid biosyntl and neolacto-series were i 24 h, most of the identifi pathways were associate acid metabolism	es: 5 min 24 circRNA ways include tered after is actor (PDGF), three time po- nd chemokine a MCAO, the e glutamater- gnaling, and MCAO, the de glutamater- gnaling, and e contraction. et Genes: or biological ant, catalytic, er, and trans- activity, ere and trans- activity were ear the regula- while genes activity were ear h MCAO, re associated ytic activity; ical processes ess, metabolic dhesion. The 5 min MCAO Hippo signal- okine receptor of xenobiotics osynthesis of gap junction, biosynthesis; atrix (ECM). etabolism of ne P450, and hesis of lacto- identified. At ed significant ed with fatty	ss highly al- circBBS2 and circPf schemia at the may serve as p ints-miRNAs tial biomarkers fo diagnosis	HKA2 poten- pr IS

			Table 1. Continued.		
Study no.	Species- Model	Microarray or se- Differentially expressed circR- Validation sample quence sample NAs (Fold change, <i>P</i> -value)	Differentially expressed GO enrichment and KEGG pathway circRNAs (Fold change, analysis <i>P</i> -value)	⁷ Interaction network of Significance circRNA-miRNA-target genes	
6 [54]	Mus musculus- Mice	transient MCAO 914 upregulated, 113 downreg- transient MCAO (45 min ischemia ulated (fold change \geq 2; <i>P</i> < sham and reperfusion at 0.05) (48 h): sham brain tissue	D:mmu-circRNA-40001Rap1 signaling pathway and the Hippot (fold change = 3.40 , $P <$ signaling pathway, which regulate cell 0.001), mmu-circRNA- survival and death 013120 (fold change = 2.43 , $P = 0.002$). Upregulated, mmu- circRNA-40806 (fold change = 0.418 , $P <$ 0.001). Downregulated	3 circRNAs-13 miRNAs- circRNAs are extensively corresponding genes, involved in brain injury af- which are related with ter stroke brain injury and recovery	
7 [55]	Mus musculus- Mice	3/group transient 283 were altered at least at 3 transient MCA0 MCAO (90 min one of the reperfusion time (90 min ischemia an ischemia and points, 16 were altered at all 3- reperfusion at 6 h reperfusion at time points of reperfusion (fold 3 sham penumbra 6 h, 12 h, and change \geq 2) cortex 24 h: 3 sham penumbral cortex	O circ-008018, circ-015350, MAPK signaling (9 genes), cell cycle (7 d circ-016128 upregulated; genes), regulation of actin cytoskeletor n: circ-011137, circ-001729, (6 genes). and focal adhesion (5 genes) al circ-006696 downregu- lated at 6 h reperfusion	 7 circ-008018-353 miRNAs; biological regulation, n circ-015350-80 miRNAs; metabolic process, cell) circ-016128-86 miRNAs; communication, response circ-001729-72 miRNAs; to stimulus circ-006696-378 miRNAs 	
8 [56]	Rattus norvegicus- Rats	MCAO: control 4745 circRNAs were identified MCAO: control brai brain tissue in both the MCAO and the tissue control group while 4630 were only identified in control group and 4319 were only identified in MCAO group; 40 were up-regulated and 47 were down-regulated circRNAs (fold changes ≥2 and <i>P</i> -values < 0.05)	n circRNA-17737, The top significant biological process circRNA-8828, circRNA- 14479, upregulated; (GO: 0007399)". The top enriched cel- circRNA-1059, circRNA- 9967, circRNA-6952 in "cytoplasmic vesicle membrane (GO downregulated 0030659)". The top significant molec- ular function was "phosphatidylinosito" binding (GO: 0035091)". The most significant pathways were referred to "Phosphatidylinositol signaling system (rn004070)," "Transcriptional misregu- lation in cancer (rn005202)" and "Endo- cytosis (rn004144)"	GircRNA-miRNA net- Needs further validation	

			L	able 1. Colluli	ucu.			
Species-	Microarray or se	- Differentially expressed circR-	Validation sample	Differentially	expressed	GO enrichment and KEGG pathwa	y Interaction netwo	rk of Significance
Model	quence sample	NAs (Fold change, <i>P</i> -value)		circRNAs (Fold	l change,	analysis	circRNA-miRNA-t	arget
				P-value)			genes	
Rattus	4 MCAO rats:	4 16 cirRNAs upregulated 28 cir-	3 h, 6 h OGD/R: nor-	hsa-circ-camk4	are ele-	glutamatergic synapse pathway, MAPI	K Circ-camk4- rn	o-miR- circ-camk4 may play a key
norvegicus-	control cerebra	l cRNAs downregulated	mal controls	vated		signaling pathway, and apoptosis signal	- 27a-3p, rno-miR3	324-3p, role in progression of cere-
Rats; Rattus	s cortex					ing pathways	rno-miR-212-3p	and bral I/R injury
norvegicus-							rno-miR-504-69	target
primary							genes	
neuronal								
cells; Homo)							
sapiens-								
SH-SY5Y								
cells								
Mus	OGD/R: norma	l 3 upregulated, 12 downregu-	OGD/R: normal con-	mmu-circRNA-0	015947	apoptosis-related, metabolism-relate	d mmu-circRNA-015	947- mmu-circRNA-015947
musculus-	controls	lated	trols	was upregulat	ed (fold	and immune-related pathways	mmu-miR-188-3p,	might be involved in
HT22 cells				change = 1.64, <i>F</i>	P = 0.01).		mmumiR-329-5p,	mmu- the process of cerebral
							miR-3057-3p, mm	u-miR- ischemia-reperfusion
							5098 and mmu-miF	R-683 injury
	Species- Model Rattus norvegicus- Rats; Rattus norvegicus- primary neuronal cells; Homo sapiens- SH-SY5Y cells Mus musculus- HT22 cells	Species- ModelMicroarray or se quence sampleRattus4 MCAO rats: - onrvegicus-Rats; Rattuscontrol cerebraRats; Rattuscortexnorvegicus-cerebraprimary-neuronal-cells; Homo-Sapiens-SH-SY5YcellsOGD/R: normamusculus-controlsHT22 cells-	Species- ModelMicroarray or se- quence sampleDifferentially expressed circR- NAs (Fold change, P-value)Rattus4 MCAO rats: 4 16 cirRNAs upregulated 28 cir- norvegicus- control cerebral cRNAs downregulated 28 cir- norvegicus- primary neuronal cells; Homo sapiens- SH-SY5Y cells4 MCAO rats: 4 16 cirRNAs upregulated 28 cir- control cerebral cRNAs downregulated cells in the second sapiens- SH-SY5Y cellsMusOGD/R: normal 3 upregulated, 12 downregulated latedHT22 cellsInternational international inte	Species- ModelMicroarray or se- quence sampleDifferentially expressed circR- Validation sample NAs (Fold change, P-value)Rattus4 MCAO rats: 4 16 cirRNAs upregulated 28 cir- control cerebral cRNAs downregulated controls3 h, 6 h OGD/R: nor- mal controlsRats; Rattuscortex cortexmal controlsnorvegicus- primary neuronal cells; Homo sapiens- SH-SY5Y cellsMusOGD/R: normal 3 upregulated, 12 downregu- latedOGD/R: normal con- trolsHT22 cells	Species- Model Microarray or se- quence sample Differentially expressed circR- NAs (Fold change, P-value) Differentially circRNAs (Fold P-value) Rattus 4 MCAO rats: 4 16 cirRNAs upregulated 28 cir- norvegicus- control cerebral cRNAs downregulated 3 h, 6 h OGD/R: nor- mal controls hsa-circ-camk4 vated Rats; Rattus cortex mal controls vated norvegicus- primary control cerebral CRNAs downregulated mal controls vated sapiens- SH-SY5Y sapiens- SH-SY5Y vated vated vated vated Mus OGD/R: normal 3 upregulated, 12 downregu- musculus- thr22 cells OGD/R: normal 3 upregulated, 12 downregu- trols vate vate	Species- Model Microarray or se- quence sample Differentially expressed circR- Validation sample quence sample Differentially expressed circRNAs (Fold change, <i>P</i> -value) Rattus 4 MCAO rats: 4 16 cirRNAs upregulated 28 cir- 3 h, 6 h OGD/R: nor- norvegicus- control cerebral cRNAs downregulated mal controls hsa-circ-camk4 are ele- vated Rattus 4 MCAO rats: 4 16 cirRNAs upregulated 28 cir- 3 h, 6 h OGD/R: nor- norvegicus- control cerebral cRNAs downregulated mal controls vated Rats; Rattus cortex norvegicus- primary neuronal cells; Homo sapiens- SH-SY5Y cells sapiengulated, 12 downregu- OGD/R: normal con- mmu-circRNA-015947 mus was upregulated (fold trols Mus OGD/R: normal 3 upregulated, 12 downregu- usculus- controls iated trols was upregulated (fold change = 1.64, <i>P</i> = 0.01).	Species- Model Microarray or se- uence sample Differentially expressed circR- Validation sample Differentially circRNAs (Fold change, analysis <i>P</i> -value) Rattus 4 MCAO rats: 4 16 cirRNAs upregulated 28 cir- control cerebral cRNAs downregulated 3 h, 6 h OGD/R: nor- mal controls hsa-circ-camk4 are vated ele- glutamatergic synapse pathway, MAPPI signaling pathway, and apoptosis signal ing pathways Rattus control cerebral cRNAs downregulated mal controls vated signaling pathway, and apoptosis signal ing pathways norvegicus- primary control cerebral cRNAs downregulated mal controls vated signaling pathways sapiens- SH-SYSY cells sapiens- SH-SYSY sapiens- sapiens- sapiens- set controls lated trols was upregulated (fold and immune-related pathways change = 1.64, <i>P</i> = 0.01).	Species- Model Microarray or se- ucre sample Differentially expressed circR- Validation sample Differentially expressed GO enrichment and KEGG pathwy Interaction network circRNAs (Fold change, nalysis Model quence sample NAs (Fold change, P-value) Differentially circRNAs (Fold change, analysis circRNA-miRNA-t genes Rattus 4 MCAO rats: 4 16 cirRNAs upregulated 28 cir- control 3 h, 6 h OGD/R: nor- mal controls hs-circ-camk4 are ele- signaling pathway, and apoptosis signal- ing pathways 27a-3p, mo-miR- mo-miR-212-3p mo-miR-504-69 norvegicus- primary control cerebral CMAs downregulated mal controls vated signaling pathways mo-miR-212-3p mo-miR-504-69 genes morvegicus- primary ro-miral ro-miR-504-69 genes mo- miR-504-69 sapiens- SH-SY5Y cells sapiens- SH-SY5Y ro-mial 3 upregulated, 12 downregu- controls oGD/R: normal 3 upregulated, 12 downregu- trols oGD/R: normal con- mus-circRNA-015947 apoptosis-related, metabolism-related mmu-circRNA-015947 Mus OGD/R: normal 3 upregulated, 12 downregu- controls trols was upregulated (fold and immune-related pathways mmu-miR-188-3p, miR-3057-3p, mm 5098 and munu-miK-

Table 1. Continued.





Fig. 2. The roles of circRNAs in stroke.

miR-60-3p [79]. Similar to other diseases, expression profile was detected by RNA-sequencing in different brain regions of PD mouse model, not comparison between case group and control group [80]. circRNAs are also suggested to behave as biomarkers in ALS [81]. Moreover, in demyelinating diseases, circRNAs either in exosomes [82] or in peripheral blood leucocytes [83] could be used as biomarkers. The expression level of ecircRNAs were significantly decreased in peripheral blood mononuclear cells of relapsing-remitting multiple sclerosis patients compared to controls [84].

7. Perspective

Up to now, the field of circRNAs research is relatively limited but rapidly developing. The research methods and databases of circRNAs have gradually matured with the efforts of global researchers. The function of circR-NAs has also been gradually expanded around the molecular sponge. circRNAs were proposed as non-coding RNAs from the beginning, but now are found to encode proteins. circRNAs also provide new detection methods and treatment approaches for several clinical diseases due to its tissue specificity and biological stability.

High expression and conservation of circRNAs in the brain should draw our attention. Many researches also indicate the part of circRNAs in the development and aging of brain. Enrichment in synaptosomes suggested that cir-RNAs might be involved in synaptic regulation. Stroke has the highest incidence of neurological diseases which has a high fatality rate and disability rate, increasing the social burden. However, researches related with stroke are limited while ICH researches are even fewer. Most original studies related with the role of circRNAs in stroke revealed an upregulation or downregulation. Differential expression

reveals its feasibility as a biomarker, either as a diagnostic or prognostic biomarker. At present, serum is widely used as clinical samples. However, due to the specificity of neural system, we could pay more attention to cerebrospinal fluid. After microarray or sequencing, expression profile is carried out and then bioinformatics analysis such as GO enrichment and KEGG pathway is performed. These results predict the function and mechanism of circRNAs and provide a basis for further research. Validation of the function of circRNAs focuses on miRNA sponge. We also speculate that circRNAs might exert the function by interacting with genes or encode proteins directly. The roles of circR-NAs in stroke were depicted in Fig. 2. With the deepening of research, we assume that in the near future we could reveal the function and mechanism of circRNAs in stroke, and further turn basic research into clinical application. It is well founded to speculate that circRNAs might be a potential therapeutic target.

8. Author contributions.

HZ and ZH propose the outline. YW searched the PubMed for relevant papers and wrote the manuscript. YW revised the paper.

9. Ethics approval and consent to participate

Not applicable.

10. Acknowledgment

We are indebted to the participants for their dedication to this study. This work was supported by grants from the National Natural Science Fund of China (grant number 81571120, 81971125).

12. Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

13. References

- [1] Chen L. The biogenesis and emerging roles of circular RNAs. Nature Reviews Molecular Cell Biology. 2016; 17: 205–211.
- [2] Vicens Q, Westhof E. Biogenesis of Circular RNAs. Cell. 2014; 159: 13–14.
- [3] Jeck WR, Sorrentino JA, Wang K, Slevin MK, Burd CE, Liu J, *et al*. Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA. 2013; 19: 141–157.
- [4] Chen W, Schuman E. Circular RNAs in brain and other tissues: a functional enigma. Trends in Neurosciences. 2016; 39: 597– 604.
- [5] Rybak-Wolf A, Stottmeister C, Glažar P, Jens M, Pino N, Giusti S, *et al*. Circular RNAs in the mammalian brain are highly abundant, conserved, and dynamically expressed. Molecular Cell. 2015; 58: 870–885.
- [6] Hu S, Cui B, Mlynash M, Zhang X, Mehta KM, Lansberg MG. Stroke epidemiology and stroke policies in China from 1980 to 2017: a systematic review and meta-analysis. International Journal of Stroke. 2020; 15: 18–28.
- [7] Keep RF, Hua Y, Xi G. Intracerebral haemorrhage: mechanisms of injury and therapeutic targets. The Lancet Neurology. 2012; 11: 720–731.
- [8] Zhu Y, Wang J, He Z, Jin F, Tang L. Association of altered serum microRNAs with perihematomal edema after acute intracerebral hemorrhage. PLoS ONE. 2015; 10: e0133783.
- [9] Wang Q, Liu X, Zhu R. Long noncoding RNAs as diagnostic and therapeutic targets for ischemic stroke. Current Pharmaceutical Design. 2019; 25: 1115–1121.
- [10] Petkovic S, Müller S. RNA circularization strategies *in vivo* and *in vitro*. Nucleic Acids Research. 2015; 43: 2454–2465.
- [11] Zhang Y, Zhang X, Chen T, Xiang J, Yin Q, Xing Y, et al. Circular intronic long noncoding RNAs. Molecular Cell. 2013; 51: 792–806.
- [12] Li Z, Huang C, Bao C, Chen L, Lin M, Wang X, *et al.* Exonintron circular RNAs regulate transcription in the nucleus. Nature Structural & Molecular Biology. 2015; 22: 256–264.
- [13] Hu Q, Zhou T. EIciRNA-mediated gene expression: tunability and bimodality. FEBS Letters. 2018; 592: 3460–3471.
- [14] Zhang Y, Xue W, Li X, Zhang J, Chen S, Zhang J, *et al.* The biogenesis of nascent circular RNAs. Cell Reports. 2016; 15: 611–624.
- [15] Ashwal-Fluss R, Meyer M, Pamudurti NR, Ivanov A, Bartok O, Hanan M, *et al.* CircRNA biogenesis competes with pre-mRNA splicing. Molecular Cell. 2014; 56: 55–66.
- [16] Conn SJ, Pillman KA, Toubia J, Conn VM, Salmanidis M, Phillips CA, *et al.* The RNA binding protein quaking regulates formation of circRNAs. Cell. 2015; 160: 1125–1134.
- [17] Hansen TB, Kjems J, Damgaard CK. Circular RNA and miR-7 in cancer. Cancer Research. 2013; 73: 5609–5612.
- [18] Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B,

Damgaard CK, *et al*. Natural RNA circles function as efficient microRNA sponges. Nature. 2013; 495: 384–388.

- [19] Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, *et al*. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 2013; 495: 333–338.
- [20] Piwecka M, Glažar P, Hernandez-Miranda LR, Memczak S, Wolf SA, Rybak-Wolf A, *et al.* Loss of a mammalian circular RNA locus causes miRNA deregulation and affects brain function. Science. 2017; 357: eaam8526.
- [21] Guo JU, Agarwal V, Guo H, Bartel DP. Expanded identification and characterization of mammalian circular RNAs. Genome Biology. 2014; 15: 409.
- [22] Schnall-Levin M, Rissland OS, Johnston WK, Perrimon N, Bartel DP, Berger B. Unusually effective microRNA targeting within repeat-rich coding regions of mammalian mRNAs. Genome Research. 2011; 21: 1395–1403.
- [23] Bolisetty MT, Graveley BR. Circuitous route to transcription regulation. Molecular Cell. 2013; 51: 705–706.
- [24] Nan A, Chen L, Zhang N, Jia Y, Li X, Zhou H, *et al.* Circular RNA circNOL10 inhibits lung cancer development by promoting SCLM1-mediated transcriptional regulation of the humanin polypeptide family. Advanced Science. 2019; 6: 1800654.
- [25] Pamudurti NR, Bartok O, Jens M, Ashwal-Fluss R, Stottmeister C, Ruhe L, *et al*. Translation of circRNAs. Molecular Cell. 2017; 66: 9–21.e7.
- [26] Hosaka T, Yamashita T, Teramoto S, Hirose N, Tamaoka A, Kwak S. ADAR2-dependent A-to-I RNA editing in the extracellular linear and circular RNAs. Neuroscience Research. 2019; 147: 48–57.
- [27] Legnini I, Di Timoteo G, Rossi F, Morlando M, Briganti F, Sthandier O, *et al*. Circ-ZNF609 is a circular RNA that can be translated and functions in myogenesis. Molecular Cell. 2017; 66: 22–37.e9.
- [28] Yang Y, Gao X, Zhang M, Yan S, Sun C, Xiao F, *et al.* Novel role of FBXW7 circular RNA in repressing glioma tumorigenesis. Journal of the National Cancer Institute. 2018; 110: 304–315.
- [29] Begum S, Yiu A, Stebbing J, Castellano L. Novel tumour suppressive protein encoded by circular RNA, circ-SHPRH, in glioblastomas. Oncogene. 2018; 37: 4055–4057.
- [30] Liang W, Wong C, Liang P, Shi M, Cao Y, Rao S, *et al.* Translation of the circular RNA circβ-catenin promotes liver cancer cell growth through activation of the Wnt pathway. Genome Biology. 2019; 20: 84.
- [31] Wang Y, Wang Z. Efficient backsplicing produces translatable circular mRNAs. RNA. 2015; 21: 172–179.
- [32] Yang Y, Fan X, Mao M, Song X, Wu P, Zhang Y, *et al.* Extensive translation of circular RNAs driven by N6-methyladenosine. Cell Research. 2017; 27: 626–641.
- [33] Abu N, Jamal R. Circular RNAs as promising biomarkers: a mini-review. Frontiers in Physiology. 2016; 7: 355.
- [34] Li Y, Zheng Q, Bao C, Li S, Guo W, Zhao J, *et al*. Circular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis. Cell Research. 2015; 25: 981–984.
- [35] Lin X, Lo H, Wong DTW, Xiao X. Noncoding RNAs in human saliva as potential disease biomarkers. Frontiers in Genetics. 2015; 6: 175.
- [36] Prefumo F. Circular RNA and pre-eclampsia: on the long road from the laboratory to the bedside. BJOG: An International Journal of Obstetrics and Gynaecology. 2016; 123: 2119.
- [37] Li H, Li K, Lai W, Li X, Wang H, Yang J, *et al.* Comprehensive circular RNA profiles in plasma reveals that circular RNAs can be used as novel biomarkers for systemic lupus erythematosus. Clinica Chimica Acta. 2018; 480: 17–25.
- [38] Ouyang Q, Wu J, Jiang Z, Zhao J, Wang R, Lou A, *et al*. Microarray expression profile of circular RNAs in peripheral blood mononuclear cells from rheumatoid arthritis patients. Cellular Physiology and Biochemistry. 2017; 42: 651–659.
- [39] Zhao Z, Li X, Jian D, Hao P, Rao L, Li M. Hsa_circ_0054633 in peripheral blood can be used as a diagnostic biomarker of pre-

diabetes and type 2 diabetes mellitus. Acta Diabetologica. 2017; 54: 237–245.

- [40] Zhuang Z, Zhang J, Luo H, Liu G, Lu Y, Ge N, et al. The circular RNA of peripheral blood mononuclear cells: Hsa_circ_0005836 as a new diagnostic biomarker and therapeutic target of active pulmonary tuberculosis. Molecular Immunology. 2017; 90: 264–272.
- [41] Zipser BD, Johanson CE, Gonzalez L, Berzin TM, Tavares R, Hulette CM, *et al.* Microvascular injury and blood-brain barrier leakage in Alzheimer's disease. Neurobiology of Aging. 2007; 28: 977–986.
- [42] Sandoval KE, Witt KA. Blood-brain barrier tight junction permeability and ischemic stroke. Neurobiology of Disease. 2008; 32: 200–219.
- [43] Garbuzova-Davis S, Hernandez-Ontiveros DG, Rodrigues MCO, Haller E, Frisina-Deyo A, Mirtyl S, *et al*. Impaired bloodbrain/spinal cord barrier in ALS patients. Brain Research. 2012; 1469: 114–128.
- [44] Chen CC, Liu L, Ma F, Wong CW, Guo XE, Chacko JV, et al. Elucidation of exosome migration across the blood-brain barrier model *in vitro*. Cellular and Molecular Bioengineering. 2016; 9: 509–529.
- [45] Xia S, Feng J, Lei L, Hu J, Xia L, Wang J, *et al.* Comprehensive characterization of tissue-specific circular RNAs in the human and mouse genomes. Briefings in Bioinformatics. 2017; 18: 984–992.
- [46] You X, Vlatkovic I, Babic A, Will T, Epstein I, Tushev G, et al. Neural circular RNAs are derived from synaptic genes and regulated by development and plasticity. Nature Neuroscience. 2015; 18: 603–610.
- [47] Xu K, Chen D, Wang Z, Ma J, Zhou J, Chen N, *et al*. Annotation and functional clustering of circRNA expression in rhesus macaque brain during aging. Cell Discovery. 2018; 4: 48.
- [48] Gruner H, Corté s-López M, Cooper DA, Bauer M, Miura P. CircRNA accumulation in the aging mouse brain. Scientific Reports. 2016; 6: 38907.
- [49] Bazan HA, Hatfield SA, Brug A, Brooks AJ, Lightell DJ, Woods TC. Carotid plaque rupture is accompanied by an increase in the ratio of serum circR-284 to miR-221 levels. Circulation Cardiovascular Genetics. 2017; 10: e001720.
- [50] Ostolaza A, Blanco-Luquin I, Urdánoz-Casado A, Rubio I, Labarga A, Zandio B, *et al*. Circular RNA expression profile in blood according to ischemic stroke etiology. Cell & Bioscience. 2020; 10: 34.
- [51] Zuo L, Zhang L, Zu J, Wang Z, Han B, Chen B, *et al*. Circulating circular RNAs as biomarkers for the diagnosis and prediction of outcomes in acute ischemic stroke. Stroke. 2020; 51: 319–323.
- [52] Dong Z, Deng L, Peng Q, Pan J, Wang Y. circRNA expression profiles and function prediction in peripheral blood mononuclear cells of patients with acute ischemic stroke. Journal of Cellular Physiology. 2020; 235: 2609–2618.
- [53] Lu D, Ho ES, Mai H, Zang J, Liu Y, Li Y, et al. Identification of blood circular RNAs as potential biomarkers for acute ischemic stroke. Frontiers in Neuroscience. 2020; 14: 81.
- [54] Liu C, Zhang C, Yang J, Geng X, Du H, Ji X, *et al*. Screening circular RNA expression patterns following focal cerebral ischemia in mice. Oncotarget. 2017; 8: 86535–86547.
- [55] Mehta SL, Pandi G, Vemuganti R. Circular RNA expression profiles alter significantly in mouse brain after transient focal ischemia. Stroke. 2017; 48: 2541–2548.
- [56] Duan X, Li L, Gan J, Peng C, Wang X, Chen W, *et al.* Identification and functional analysis of circular RNAs induced in rats by middle cerebral artery occlusion. Gene. 2019; 701: 139–145.
- [57] Zhang Z, Wang Y, Li F, Liu X, Zhang H, Zhu Z, *et al.* Circcamk4 involved in cerebral ischemia/reperfusion induced neuronal injury. Scientific Reports. 2020; 10: 7012.
- [58] Lin S, Ye S, Long Y, Fan Y, Mao H, Chen M, *et al.* Circular RNA expression alterations are involved in OGD/R-induced neuron injury. Biochemical and Biophysical Research Commu-

nications. 2016; 471: 52-56.

- [59] Peng X, Jing P, Chen J, Xu L. The role of circular RNA HECTD1 expression in disease risk, disease severity, inflammation, and recurrence of acute ischemic stroke. Journal of Clinical Laboratory Analysis. 2019; 33: e22954.
- [60] Zhu X, Ding J, Wang B, Wang J, Xu M. Circular RNA DL-GAP4 is down-regulated and negatively correlates with severity, inflammatory cytokine expression and pro-inflammatory gene miR-143 expression in acute ischemic stroke patients. International Journal of Clinical and Experimental Pathology. 2019; 12: 941–948.
- [61] Wang G, Han B, Shen L, Wu S, Yang L, Liao J, et al. Silencing of circular RNA HIPK2 in neural stem cells enhances functional recovery following ischaemic stroke. EBioMedicine. 2020; 52: 102660.
- [62] Bai Y, Zhang Y, Han B, Yang L, Chen X, Huang R, et al. Circular RNA DLGAP4 ameliorates ischemic stroke outcomes by targeting miR-143 to regulate endothelial-mesenchymal transition associated with blood-brain barrier integrity. The Journal of Neuroscience. 2018; 38: 32–50.
- [63] Han B, Zhang Y, Zhang Y, Bai Y, Chen X, Huang R, et al. Novel insight into circular RNA HECTD1 in astrocyte activation via autophagy by targeting MIR142-TIPARP: implications for cerebral ischemic stroke. Autophagy. 2019; 14: 1164–1184.
- [64] Wu F, Han B, Wu S, Yang L, Leng S, Li M, *et al*. Circular RNA TLK1 aggravates neuronal injury and neurological deficits after ischemic stroke via miR-335-3p/TIPARP. The Journal of Neuroscience. 2019; 39: 7369–7393.
- [65] Dou Z, Yu Q, Wang G, Wu S, Reis C, Ruan W, *et al.* Circular RNA expression profiles alter significantly after intracerebral hemorrhage in rats. Brain Research. 2020; 1726: 146490.
- [66] Dube U, Del-Aguila JL, Li Z, Budde JP, Jiang S, Hsu S, *et al.* An atlas of cortical circular RNA expression in Alzheimer disease brains demonstrates clinical and pathological associations. Nature Neuroscience. 2019; 22: 1903–1912.
- [67] Huang J, Qin M, Zhou Y, Xu Z, Yang S, Zhang F, et al. Comprehensive analysis of differentially expressed profiles of Alzheimer's disease associated circular RNAs in an Alzheimer's disease mouse model. Aging. 2018; 10: 253–265.
- [68] Li Y, Fan H, Sun J, Ni M, Zhang L, Chen C, *et al*. Circular RNA expression profile of Alzheimer's disease and its clinical significance as biomarkers for the disease risk and progression. The International Journal of Biochemistry & Cell Biology. 2020; 123: 105747.
- [69] Ma N, Pan J, Ye X, Yu B, Zhang W, Wan J. Wholetranscriptome analysis of APP/PS1 mouse brain and identification of circRNA-miRNA-mRNA networks to investigate AD pathogenesis. Molecular Therapy-Nucleic Acids. 2019; 18: 1049–1062.
- [70] Wang Z, Xu P, Chen B, Zhang Z, Zhang C, Zhan Q, *et al.* Identifying circRNA-associated-ceRNA networks in the hippocampus of Abeta1-42-induced Alzheimer's disease-like rats using microarray analysis. Aging. 2018; 10: 775–788.
- [71] Zhang S, Zhu D, Li H, Li H, Feng C, Zhang W. Characterization of circRNA-associated-ceRNA networks in a senescenceaccelerated mouse prone 8 brain. Molecular Therapy. 2017; 25: 2053–2061.
- [72] Zhang Y, Yu F, Bao S, Sun J. Systematic characterization of circular RNA-Associated CeRNA network identified novel circRNA biomarkers in Alzheimer's disease. Frontiers in Bioengineering and Biotechnology. 2019; 7: 222.
- [73] Diling C, Yinrui G, Longkai Q, Xiaocui T, Yadi L, Xin Y, et al. Circular RNA NF1-419 enhances autophagy to ameliorate senile dementia by binding Dynamin-1 and Adaptor protein 2 B1 in AD-like mice. Aging. 2019; 11: 12002–12031.
- [74] Yang H, Wang H, Shang H, Chen X, Yang S, Qu Y, et al. Circular RNA circ_0000950 promotes neuron apoptosis, suppresses neurite outgrowth and elevates inflammatory cytokines levels via directly sponging miR-103 in Alzheimer's disease. Cell Cy-

cle. 2019; 18: 2197–2214.

- [75] Lu Y, Tan L, Wang X. Circular HDAC9/microRNA-138/Sirtuin-1 pathway mediates synaptic and amyloid precursor protein processing deficits in Alzheimer's disease. Neuroscience Bulletin. 2019; 35: 877–888.
- [76] Shi Z, Chen T, Yao Q, Zheng L, Zhang Z, Wang J, *et al*. The circular RNA ciRS-7 promotes APP and BACE1 degradation in an NF-kappaB-dependent manner. The FEBS Journal. 2017; 284: 1096–1109.
- [77] Zhao Y, Alexandrov PN, Jaber V, Lukiw WJ. Deficiency in the ubiquitin conjugating enzyme UBE2a in Alzheimer's disease (AD) is linked to deficits in a natural circular miRNA-7 sponge (circRNA; ciRS-7). Genes. 2016; 7: 116.
- [78] Feng Z, Zhang L, Wang S, Hong Q. Circular RNA circDL-GAP4 exerts neuroprotective effects via modulating miR-134-5p/CREB pathway in Parkinson's disease. Biochemical and Biophysical Research Communications. 2020; 522: 388–394.
- [79] Kumar L, Shamsuzzama, Jadiya P, Haque R, Shukla S, Nazir A. Functional Characterization of Novel Circular RNA Molecule, circzip-2 and its Synthesizing Gene zip-2 in C. elegans Model of Parkinson's Disease. Molecular Neurobiology. 2018; 55: 6914– 6926.
- [80] Jia E, Zhou Y, Liu Z, Wang L, Ouyang T, Pan M, et al. Transcriptomic profiling of circular RNA in different brain regions of Parkinson's disease in a mouse model. International Journal of Molecular Sciences. 2020; 21: 3006.
- [81] Dolinar A, Koritnik B, Glavač D, Ravnik-Glavač M. Circular RNAs as potential blood biomarkers in amyotrophic lateral sclerosis. Molecular Neurobiology. 2019; 56: 8052–8062.
- [82] He J, Ren M, Li H, Yang L, Wang X, Yang Q. Exosomal circular RNA as a biomarker platform for the early diagnosis of immune-mediated demyelinating disease. Frontiers in Genetics. 2019; 10: 860.
- [83] Iparraguirre L, Muñoz-Culla M, Prada-Luengo I, Castillo-Triviño T, Olascoaga J, Otaegui D. Circular RNA profiling reveals that circular RNAs from ANXA2 can be used as new biomarkers for multiple sclerosis. Human Molecular Genetics. 2017; 26: 3564–3572.
- [84] Cardamone G, Paraboschi EM, Rimoldi V, Duga S, Soldà G, Asselta R. The characterization of GSDMB splicing and backsplicing profiles identifies novel isoforms and a circular RNA that are dysregulated in multiple sclerosis. International Journal of Molecular Sciences. 2017; 18: 576.

Abbreviations: BBB, blood brain barrier; cAMP, cyclic adenosine monophosphate; CDR1, Cerebellar degeneration related 1; circRNAs, Circular RNAs; circSRY, Sex-determining region Y of testicular-specific circRNA; ciRNAs, Circular intronic RNAs; ecircRNAs, Circular

exonic RNAs; EIciRNAs, Exon-intron circular RNAs; EMT, epithelial-mesenchymal transition; exoG, Exogenous guanosine; GO, Gene Ontology; HECTD1, homologous to the E6-AP C-terminal domain E3 ubiquitin protein ligase 1; HTS, High-throughput sequencing; ICH, Intracerebral hemorrhage; IS, Ischemic stroke; IRES, Internal ribosome entry site; I/R, ischemia-reperfusion; KEGG, Kyoto Encyclopedia of Genes and Genomes; MAPK, mitogen-activated protein kinase; MBL, Muscleblind protein; MCAO, middle cerebral artery occlusion; miRNAs, microRNAs; MND, motor neuron disease; NSCs, neural stem cells; OGD/R, oxygen-glucose deprivation/reoxygenation; PBMCs, peripheral blood mononuclear cells; PI3K-Akt, phosphatidylinositol 3 kinase/protein kinase B; Pol II, polymerase II; poly A, Poly-adenylated; pre-mRNA, messenger RNA precursors; QKI, Quaking protein; gRT-PCR, quantitative reverse transcription polymerase chain reaction; Rap1, Ras-associated protein 1; SCML1, Sex comb on midleg-like 1; snRNA, small nuclear RNA; snRNP, small nuclear ribonucleoprotein; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; TF, Transcription Factor; TIPARP, poly [ADP-ribose] polymerase; TNF, tumor necrosis factor; Wnt, Wingless/Integrated; ω G, terminal guanosine.

Keywords: Review; Circular RNAs; Stroke; Biomarker; miRNA sponge

Send correspondence to: He-Yu Zhang, Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University; Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, No.58 Zhongshan Road 2, 510080 Guangzhou, Guangdong, China, E-mail: heyuzhang0226@163.com

Zhi-Yi He, Department of Neurology, Key Laboratory for Neurological Big Data of Liaoning Province, The First Affiliated Hospital of China Medical University, 110001 Shenyang, Liaoning, China, E-mail: hezhiyi0301@sina.com